moremroemroe
459 posts




Nice note out this morning from Jefferies on $TMDX -- - reiterates buy rating - price target increased to $155 for base case - price target increased to $200 for bull case - $TMDX unveiled hypothermic CHOPS last week at ISHLT, more hypothermic products will be added in the future including cold perfusion... CHOPS has been in development for several years and should be complimentary to OCS (warm perfusion) for certain cases - Enhance (part A) trials for Heart OCS 2.0 are 50% enrolled - Denovo (part B) trials for Lung OCS 2.0 are just getting started - Impact from higher fuel prices is manageable because NOP is still the most efficient logistics network for organ transports, $TMDX will pass through the higher fuel costs and won't try to make a profit NFA. DYOR. *I own $TMDX personally and so does @FirstWaveFund Personally I think $TMDX is extremely compelling at these prices... (using my estimates)... $TMDX is currently trading at 4.5x NTM revs and 22.5x 2027 EPS... I think EPS compounds at a 35% CAGR over the next 5 years.







$SNDK in 12 Monaten: +2.974%. $1.000 → $30.740 $5.000 → $153.702 $10.000 → $307.405 $33.000 → $1.000.000 War ich dabei? Nein. Man kann nicht jeden Tenbagger erwischen. Aber 4 von 10 meiner Aktien wurden es bereits. Deshalb analysiere ich täglich. Das nächste $SNDK ist _____👇









